Merck Sharp Dohme Company Profile

What is the competitive landscape for MERCK SHARP DOHME

MERCK SHARP DOHME has twenty-one approved drugs.

There are eighteen US patents protecting MERCK SHARP DOHME drugs.

There are four hundred and one patent family members on MERCK SHARP DOHME drugs in fifty-six countries and eighty-six supplementary protection certificates in nineteen countries.

Summary for Merck Sharp Dohme

International Patents:	401
US Patents:	18
Tradenames:	17
Ingredients:	17
NDAs:	21

Drugs and US Patents for Merck Sharp Dohme

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	AB	RX	Yes	Yes	7,326,708*PED				Y
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	9,493,582		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No	10,098,892		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No	7,951,797		Y	Y
Merck Sharp Dohme	PREVYMIS	letermovir	SOLUTION;INTRAVENOUS	209940-002	Nov 8, 2017		RX	Yes	Yes
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998		DISCN	No	No

Expired US Patents for Merck Sharp Dohme

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-003	Oct 7, 2011	6,890,898
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	7,459,428
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-001	Oct 7, 2011	7,459,428
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001	6,461,605*PED
Merck Sharp Dohme	DUTREBIS	lamivudine; raltegravir potassium	TABLET;ORAL	206510-001	Feb 6, 2015	7,435,734*PED
Merck Sharp Dohme	TEMODAR	temozolomide	CAPSULE;ORAL	021029-004	Aug 11, 1999	5,260,291*PED

Paragraph IV (Patent) Challenges for MERCK SHARP DOHME drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	140 mg and 180 mg		2008-03-24
	Delayed-release Tablets	100 mg		2014-06-16
	Tablets	25 mg, 50 mg and 100 mg		2010-10-18
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-25
	Oral Suspension	40 mg/mL		2011-02-28
	Injection	18 mg/mL, 16.7 mL vials		2015-11-24
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-19
	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg		2012-11-06

International Patents for Merck Sharp Dohme Drugs

Country	Patent Number	Estimated Expiration
South Korea	101350420
Tunisia	2014000345
South Africa	201405949
Croatia	P20211686
Taiwan	I513696
Argentina	063979

Supplementary Protection Certificates for Merck Sharp Dohme Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1385870	C 2011 014	Romania		PRODUCT NAME: BOCEPREVIR(1R,2S,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/704/001; DATE OF NATIONAL AUTHORISATION: 20110718; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/704/001; DATE OF FIRST AUTHORISATION IN EEA: 20110718
1385870	SPC/GB11/057	United Kingdom		PRODUCT NAME: BOCEPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/704/001 20110720
1412357	122008000046	Germany		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408
1622880	300933	Netherlands		PRODUCT NAME: LETERMOVIR; REGISTRATION NO/DATE: EU/1/17/1245 20180110
0817637	05C0022	France		PRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Merck
• Merck And Co Inc
• Merck Kgaa
• Merck Sharp Dohme

Pharmaceutical Competitive Landscape Analysis: MERCK SHARP DOHME – Market Position, Strengths & Strategic Insights

Last updated: February 2, 2026

Summary

Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., stands as a leading global player in the pharmaceutical industry. With a robust portfolio spanning oncology, vaccines, infectious diseases, and cardiovascular therapies, MSD commands significant market share across major regions—North America, Europe, and emerging markets. This report provides a comprehensive analysis of MSD’s market position, core strengths, strategic initiatives, and the competitive dynamics shaping its growth trajectory.

---

What Is Merck Sharp & Dohme’s Market Position?

Global Standing and Revenue Impact

• 2022 Revenue: USD 59.3 billion, with approximately 54% generated in North America.
• Top Therapeutic Areas:
  • Oncology (e.g., KEYTRUDA)
  • Vaccines (e.g., Gardasil, Pneumovax)
  • Infectious Diseases (e.g., Bridgit, Ervebro)
  • Cardiovascular and Endocrinology (e.g., Januvia)

Market Share and Competitive Ranking

Region	Major Competitors	Estimated Market Share (%)	Key Products & Differentiators
North America	Pfizer, Johnson & Johnson, Novartis	Merck: ~25-30%	KEYTRUDA leading in oncology, strong vaccine portfolio
Europe	GlaxoSmithKline, Sanofi, Roche	Merck: ~20-25%	Innovative immunotherapy, vaccines
Asia-Pacific	GSK, local generic manufacturers	Merck: ~10-15%	Expansion via alliances, localized manufacturing

Strategic Market Focus

• High-growth emerging markets: India, China, Latin America.
• Innovation-driven pipeline: Focus on immuno-oncology, mRNA technology, and biologics.
• Partnership and licensing: Collaborations with biotech firms (e.g., AstraZeneca, Pfizer).

---

What Are Merck Sharp & Dohme’s Core Strengths?

Robust R&D Pipeline

Focus Area	Notable Drugs/Technologies	Development Stage	Strategic Advantage
Oncology	KEYTRUDA (pembrolizumab)	Blockbuster, approved in >100 indications	Market leader, broad clinical use, high revenues
Vaccines	Gardasil, Pneumovax, RotaTeq	Established, expanding indications	Strong immunization franchise, high global coverage
Infectious Diseases	Belsomra, Bridgit (recently approved)	Phase 3/4	Diversification, early pipeline strength
Biologics & Biosimilars	Rituxan (biosimilar development), biologics	Various	Competitive entry, cost-effective alternatives

Significant Market Presence & Brand Recognition

• KEYTRUDA: Ranked #1 in oncology immunotherapies, with sales exceeding USD 17 billion in 2022.
• Vaccine portfolio: Leading provider with over 80 years of established immunization products.
• Global infrastructure: 60 manufacturing sites, extensive distribution channels.

Strategic Partnerships & Alliances

Partner/Collaborator	Focus Area	Purpose	Duration
AstraZeneca	Oncology, Immunotherapy	Co-develop and commercialize drugs	2017-present
Ridgeback Biotherapeutics	Infectious Diseases	R&D collaboration for antiviral therapies	2020-present
GSK	Vaccines	Joint vaccine development	Various agreements

Regulatory & Patent Strategies

• Proactive patent filings and defenses for blockbuster drugs.
• Strategic patent extensions through supplementary indications.

---

What Are the Key Challenges and Risks Facing MSD?

Challenge/Risk	Impact	Mitigation Strategies
Patent expirations	Revenue decline for some blockbuster drugs	Diversification, new drug launches
Pricing & reimbursement pressures	Reduced profit margins	Cost management, market access strategies
Intense competition (e.g., emerging biosimilars)	Market share erosion	Innovation, pipeline expansion
Regulatory hurdles	Delays in drug approvals, increased costs	Robust regulatory compliance, early engagement

---

What Are Strategic Opportunities for MSD?

Pipeline Innovation & Digital Transformation

• Launch of novel immuno-oncology agents and personalized medicine.
• Integration of artificial intelligence (AI) in R&D to accelerate drug discovery.

Expansion in Emerging Markets

Region	Opportunity	Strategy
China	Growing healthcare infrastructure	Local manufacturing, partnerships with local companies
India	Large patient population, unmet medical needs	Investment in manufacturing, licensing agreements
Latin America	Increasing health expenditure, immunization coverage	Market entry via joint ventures, public health agreements

Focus on Biosimilars and Cost-Effective Therapies

• Leverage biosimilars to reduce costs and expand access.
• Target patent expirations with competitive biosimilar launches (e.g., Rituxan biosimilar in 2023).

Embrace Digital & Data-Driven Approaches

• Implement digital health tools for remote patient monitoring.
• Utilize real-world evidence for regulatory submissions and market insights.

---

How Does MSD Compare Against Key Competitors?

Comparable Competitor Overview

Company	Revenue (2022)	Focus Areas	Notable Drugs	Market Strategy
Pfizer	USD 100.3B	Vaccines, Oncology, Rare Diseases	Prevnar, Ibrance	Diversified portfolio, M&A focus
Roche	USD 63.8B	Oncology, Diagnostics	Herceptin, Rituxan	Diagnostics integration
Johnson & Johnson	USD 94.9B	Consumer Health, Pharmaceuticals	Stelara, Darzalex	Consumerbrand synergies
Sanofi	USD 42.9B	Vaccines, Rare Diseases	Dupixent, Fluzone	Focus on immunology and vaccines

SWOT Analysis for MSD

Strengths	Weaknesses	Opportunities	Threats
Leading immuno-oncology portfolio	Dependence on KEYTRUDA sales	Growth in emerging markets	Patent cliff for key drugs
Strong vaccine presence	Patent expirations for older drugs	Diversification into biologics	Biosimilar competition
Extensive R&D pipeline	High R&D expenditure	Digital health innovation	Regulatory complexities

---

Conclusion & Key Takeaways

• Market Position: MSD is a top-tier global pharmaceutical leader, driven by its blockbuster immuno-oncology agent and a diversified vaccine portfolio.
• Strengths: Dominant R&D pipeline, strong brand recognition, global manufacturing and distribution infrastructure.
• Strategic Focus: Expanding in emerging markets, investing in innovative therapies, leveraging biosimilars, and digital integration.
• Challenges: Patent expirations, pricing pressures, biosimilar threats, regulatory hurdles.
• Opportunities: Rapid pipeline development, personalized medicine, bios_B alias, expanding novel immunotherapies, and digital health.
• Competitive Dynamics: Remains competitive with Pfizer, Roche, J&J, and Sanofi through innovation and market expansion strategies.

Actionable Insights

• Monitor patent expiry timelines and prepare for biosimilar competition.
• Accelerate investments in early-stage biotech collaborations.
• Focus on tailored market entry strategies in high-growth emerging regions.
• Leverage digital technologies for enhanced R&D productivity and patient engagement.
• Maintain flexibility to adapt to regulatory environments while safeguarding innovation pipelines.

---

Frequently Asked Questions (FAQs)

Q1: What are MSD’s most lucrative therapeutic areas?
Oncology, vaccines, and infectious diseases are MSD’s primary revenue drivers, with KEYTRUDA driving over USD 17 billion in 2022.

Q2: How does MSD plan to sustain growth amid patent expirations?
Through pipeline diversification, biosimilar strategies, and expanding into emerging markets with localized products.

Q3: What are MSD’s leading COVID-19 vaccine initiatives?
While MSD does not produce COVID-19 vaccines, it focuses on collaborations and pipeline development in infectious diseases to capitalize on post-pandemic healthcare needs.

Q4: How is MSD leveraging digital health technologies?
Investments include remote patient monitoring, AI-driven drug discovery, and real-world evidence analytics.

Q5: How does MSD compare to Pfizer in terms of innovation?
MSD leads in immuno-oncology with KEYTRUDA, whereas Pfizer has diversified in mRNA platforms like Comirnaty. Both invest heavily in pipeline expansion and technological innovation.

---

Sources Cited

1. Merck & Co. Annual Report 2022.
2. EvaluatePharma Oncology Reports 2022.
3. IQVIA Institute: The Global Use of Medicines in 2022.
4. Company press releases and strategic updates (2021-2023).